Redefining the Standard of Care: The PROGRESS Trial Challenges the "Wait and See" Approach to Moderate Aortic Stenosis on November 3, 2026 Posted by
Decoding the Immune Stalemate: A New Frontier in Treating Chronic Diabetic Ulcers on November 3, 2026 Posted by
NewYork-Presbyterian and Spear Forge Landmark Partnership to Revolutionize Outpatient Rehabilitation Access Across NYC and Westchester on November 3, 2026 Posted by
Beyond the Salt Shaker: Why Potassium is the Missing Link in Global Heart Health on November 3, 2026 Posted by
Navigating the Future of Nutrition: A Comprehensive Review of the 2022-2023 Healthy Living Landscape on November 3, 2026 Posted by
Redefining the Standard of Care: The PROGRESS Trial Challenges the "Wait and See" Approach to Moderate Aortic Stenosis on November 3, 2026 Posted by
Decoding the Immune Stalemate: A New Frontier in Treating Chronic Diabetic Ulcers on November 3, 2026 Posted by
NewYork-Presbyterian and Spear Forge Landmark Partnership to Revolutionize Outpatient Rehabilitation Access Across NYC and Westchester on November 3, 2026 Posted by
Posted in Digital Health Tools The New Frontier of Biotech: Roivant’s Clinical Gains, Obesity Drug Innovation, and the Paradox of Access on September 8, 2026
Posted in Digital Health Tools A Breath of Fresh Air: Roivant’s Mosliciguat Shows Promise in Treating Pulmonary Hypertension on September 8, 2026
Posted in Digital Health Tools A New Era for Dermatomyositis: Roivant Sciences Secures Historic FDA Approval for Lisraya on August 28, 2026
Posted in Medical Innovations Biotech Pulse: Roivant’s Regulatory Milestone, Cytokinetics’ Cardiology Data, and the Ethics of Academic Research on August 28, 2026
Posted in Medical Innovations A New Frontier in Dermatomyositis: FDA Approval of Lisraya Marks a Pivot Point for Roivant on August 27, 2026